您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Bumetanide
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Bumetanide
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Bumetanide图片
CAS NO:28395-03-1
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
1g电议
5g电议

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt364.42
Cas No.28395-03-1
FormulaC17H20N2O5S
Solubilityinsoluble in H2O; ≥18.22 mg/mL in DMSO; ≥4.04 mg/mL in EtOH
Chemical Name3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
Canonical SMILESCCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Loop diuretic that inhibits the Na+/2Cl-/K+(NKCC) cotransporter. More potent than furosemide.

试验操作

Cell experiment:[1]

Cell lines

NKCC1A-expressingXenopusoocytes

Reaction Conditions

0.03 ~ 100 μM bumetanide for 5 min incubation

Applications

Bumetanide inhibited the86Rb+uptake in NKCC1A-expressing oocytes in a dose-dependent manner. At the doses ranging from 30 to 100 μM, bumetanide reduced the86Rb+uptake to background levels.

Animal experiment:[2]

Animal models

Dogs

Dosage form

0.1 mg/kg

Injected intravenously

Applications

Bumetanide (0.1 mg/kg) significantly increased urine flow and sodium and potassium excretion, as well as decreased sodium reabsorption, in anesthetized dogs. In addition, bumetanide was approximately 30-fold more potent than furosemide in enhancing sodium excretion.

Note

The technical data provided above is for reference only.

References:

1. Lykke K, Tollner K, Feit PW, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy & Behavior, 2016, 59: 42-49.

2. Cohen MR, Hinsch E, Vergona R, et al. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. Journal of Pharmacology and Experimental Therapeutics, 1976, 197(3): 697-702.